- Home
- ROC vs NTRB Comparison
ROC vs NTRB Comparison
Compare ROC & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROC | NTRB |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.6M | 72.6M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ROC | NTRB |
|---|---|---|
| Price | $4.34 | $5.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | 22.2K | ★ 42.9K |
| Earning Date | 03-31-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,979,679.00 | $2,036,651.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.90 | N/A |
| 52 Week Low | $3.71 | $2.80 |
| 52 Week High | $7.80 | $8.63 |
Technical Indicators
Market Signals| Indicator | ROC | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 72.84 |
| Support Level | $4.26 | $4.23 |
| Resistance Level | $5.29 | $6.41 |
| Average True Range (ATR) | 0.23 | 0.62 |
| MACD | 0.04 | 0.16 |
| Stochastic Oscillator | 40.31 | 77.98 |
Price Performance
Historical ComparisonAbout ROC Rank One Computing Corporation Common stock
Rank One Computing Corp is an American artificial intelligence company. It develops AI systems that analyze visual data to identify and interpret objects and activities. The company's focus is on biometric identity, digital forensics, and real-time video analytics. It uses the term 'Vision AI,' which is an operational AI built for accuracy, speed, and auditability. The company generates revenue from the sale of access to its software platforms, maintenance services, and professional services.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.